- Home
- SCYX
SCYX
SCYNEXIS Inc.
as of 12-05-2025 3:32pm EST
SCYNEXIS Inc is a drug development company that focuses on the development and commercialization of novel anti-infectives to address unmet therapeutic needs. It is engaged in developing a product candidate, ibrexafungerp which is a novel oral and intravenous (IV) drug for the treatment of several fungal infections, including serious and life-threatening invasive fungal infections. The ibrexafungerp is a novel and structurally distinct triterpenoid glucan synthase inhibitor that is effective in vitro and in vivo against broad range of Candida and Aspergillus species, including drug-resistant strains as well as Pneumocystis, Coccidioides, Histoplasma and Blastomyces genera and some common mucorales species.
| Founded: | 1999 | Country: | United States |
| Employees: | N/A | City: | JERSEY CITY |
| Market Cap: | 24.6M | IPO Year: | 2014 |
| Target Price: | $3.00 | AVG Volume (30 days): | 563.4K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 1 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.51 | EPS Growth: | N/A |
| 52 Week Low/High: | $0.56 - $1.49 | Next Earning Date: | 11-05-2025 |
| Revenue: | $2,932,000 | Revenue Growth: | -65.77% |
| Revenue Growth (this year): | 167.73% | Revenue Growth (next year): | 290.78% |
AI-Powered SCYX Daily Prediction
Machine learning model trained on 25+ technical indicators
AI Recommendation
Disclaimer: This prediction is generated by an AI model and should not be considered as financial advice. Always conduct your own research and consult with financial professionals before making investment decisions.
Compare SCYX vs Leading Stocks
See how SCYX stacks up against similar companies in the market
Head-to-Head Comparisons
Share on Social Networks:
Tools & Resources
Enhance your trading experience with our free tools
Disclaimer
The information presented on this page, "SCYX SCYNEXIS Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.